The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Kidney & Renal Fibrosis Treatment Market Research Report 2025
Synopsis
Kidney/Renal fibrosis, defined as an aberrant wound healing process in response to chronic injury, is characterized by the progressive and persistent accumulation of extracellular matrix components (ECM) in the kidney, ultimately leading to renal failure.
The global Kidney & Renal Fibrosis Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Kidney & Renal Fibrosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney & Renal Fibrosis Treatment.
Report Scope
The Kidney & Renal Fibrosis Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kidney & Renal Fibrosis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney & Renal Fibrosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Galectin Therapeutics
Merck & Co.
F. Hoffman-La Roche Ltd.
Pfizer Inc.
InterMune Inc.
ProMetic Life-Sciences Inc.
La Jolla Pharmaceutical Company
Genzyme Corporation
BioLine Rx Ltd
Segment by Type
Angiotensin II Receptor Blockers (ARBs)
Angiotensin Converting Enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Vasopeptidase Inhibitors
Segment by Application
Commercial/Private Hospitals
Public Health Hospitals
Clinics
Home Treatment
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney & Renal Fibrosis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Kidney/Renal fibrosis, defined as an aberrant wound healing process in response to chronic injury, is characterized by the progressive and persistent accumulation of extracellular matrix components (ECM) in the kidney, ultimately leading to renal failure.
The global Kidney & Renal Fibrosis Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Kidney & Renal Fibrosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney & Renal Fibrosis Treatment.
Report Scope
The Kidney & Renal Fibrosis Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kidney & Renal Fibrosis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney & Renal Fibrosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Galectin Therapeutics
Merck & Co.
F. Hoffman-La Roche Ltd.
Pfizer Inc.
InterMune Inc.
ProMetic Life-Sciences Inc.
La Jolla Pharmaceutical Company
Genzyme Corporation
BioLine Rx Ltd
Segment by Type
Angiotensin II Receptor Blockers (ARBs)
Angiotensin Converting Enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Vasopeptidase Inhibitors
Segment by Application
Commercial/Private Hospitals
Public Health Hospitals
Clinics
Home Treatment
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney & Renal Fibrosis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney & Renal Fibrosis Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Angiotensin II Receptor Blockers (ARBs)
1.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors
1.2.4 Pirfenidone
1.2.5 Renin Inhibitors
1.2.6 Vasopeptidase Inhibitors
1.3 Market by Application
1.3.1 Global Kidney & Renal Fibrosis Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Commercial/Private Hospitals
1.3.3 Public Health Hospitals
1.3.4 Clinics
1.3.5 Home Treatment
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kidney & Renal Fibrosis Treatment Market Perspective (2019-2030)
2.2 Kidney & Renal Fibrosis Treatment Growth Trends by Region
2.2.1 Global Kidney & Renal Fibrosis Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Kidney & Renal Fibrosis Treatment Historic Market Size by Region (2019-2024)
2.2.3 Kidney & Renal Fibrosis Treatment Forecasted Market Size by Region (2025-2030)
2.3 Kidney & Renal Fibrosis Treatment Market Dynamics
2.3.1 Kidney & Renal Fibrosis Treatment Industry Trends
2.3.2 Kidney & Renal Fibrosis Treatment Market Drivers
2.3.3 Kidney & Renal Fibrosis Treatment Market Challenges
2.3.4 Kidney & Renal Fibrosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kidney & Renal Fibrosis Treatment Players by Revenue
3.1.1 Global Top Kidney & Renal Fibrosis Treatment Players by Revenue (2019-2024)
3.1.2 Global Kidney & Renal Fibrosis Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Kidney & Renal Fibrosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Kidney & Renal Fibrosis Treatment Revenue
3.4 Global Kidney & Renal Fibrosis Treatment Market Concentration Ratio
3.4.1 Global Kidney & Renal Fibrosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney & Renal Fibrosis Treatment Revenue in 2023
3.5 Kidney & Renal Fibrosis Treatment Key Players Head office and Area Served
3.6 Key Players Kidney & Renal Fibrosis Treatment Product Solution and Service
3.7 Date of Enter into Kidney & Renal Fibrosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Kidney & Renal Fibrosis Treatment Breakdown Data by Type
4.1 Global Kidney & Renal Fibrosis Treatment Historic Market Size by Type (2019-2024)
4.2 Global Kidney & Renal Fibrosis Treatment Forecasted Market Size by Type (2025-2030)
5 Kidney & Renal Fibrosis Treatment Breakdown Data by Application
5.1 Global Kidney & Renal Fibrosis Treatment Historic Market Size by Application (2019-2024)
5.2 Global Kidney & Renal Fibrosis Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Kidney & Renal Fibrosis Treatment Market Size (2019-2030)
6.2 North America Kidney & Renal Fibrosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Kidney & Renal Fibrosis Treatment Market Size by Country (2019-2024)
6.4 North America Kidney & Renal Fibrosis Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kidney & Renal Fibrosis Treatment Market Size (2019-2030)
7.2 Europe Kidney & Renal Fibrosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Kidney & Renal Fibrosis Treatment Market Size by Country (2019-2024)
7.4 Europe Kidney & Renal Fibrosis Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kidney & Renal Fibrosis Treatment Market Size (2019-2030)
8.2 Asia-Pacific Kidney & Renal Fibrosis Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Kidney & Renal Fibrosis Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Kidney & Renal Fibrosis Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kidney & Renal Fibrosis Treatment Market Size (2019-2030)
9.2 Latin America Kidney & Renal Fibrosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Kidney & Renal Fibrosis Treatment Market Size by Country (2019-2024)
9.4 Latin America Kidney & Renal Fibrosis Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kidney & Renal Fibrosis Treatment Market Size (2019-2030)
10.2 Middle East & Africa Kidney & Renal Fibrosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Kidney & Renal Fibrosis Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Kidney & Renal Fibrosis Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Galectin Therapeutics
11.1.1 Galectin Therapeutics Company Detail
11.1.2 Galectin Therapeutics Business Overview
11.1.3 Galectin Therapeutics Kidney & Renal Fibrosis Treatment Introduction
11.1.4 Galectin Therapeutics Revenue in Kidney & Renal Fibrosis Treatment Business (2019-2024)
11.1.5 Galectin Therapeutics Recent Development
11.2 Merck & Co.
11.2.1 Merck & Co. Company Detail
11.2.2 Merck & Co. Business Overview
11.2.3 Merck & Co. Kidney & Renal Fibrosis Treatment Introduction
11.2.4 Merck & Co. Revenue in Kidney & Renal Fibrosis Treatment Business (2019-2024)
11.2.5 Merck & Co. Recent Development
11.3 F. Hoffman-La Roche Ltd.
11.3.1 F. Hoffman-La Roche Ltd. Company Detail
11.3.2 F. Hoffman-La Roche Ltd. Business Overview
11.3.3 F. Hoffman-La Roche Ltd. Kidney & Renal Fibrosis Treatment Introduction
11.3.4 F. Hoffman-La Roche Ltd. Revenue in Kidney & Renal Fibrosis Treatment Business (2019-2024)
11.3.5 F. Hoffman-La Roche Ltd. Recent Development
11.4 Pfizer Inc.
11.4.1 Pfizer Inc. Company Detail
11.4.2 Pfizer Inc. Business Overview
11.4.3 Pfizer Inc. Kidney & Renal Fibrosis Treatment Introduction
11.4.4 Pfizer Inc. Revenue in Kidney & Renal Fibrosis Treatment Business (2019-2024)
11.4.5 Pfizer Inc. Recent Development
11.5 InterMune Inc.
11.5.1 InterMune Inc. Company Detail
11.5.2 InterMune Inc. Business Overview
11.5.3 InterMune Inc. Kidney & Renal Fibrosis Treatment Introduction
11.5.4 InterMune Inc. Revenue in Kidney & Renal Fibrosis Treatment Business (2019-2024)
11.5.5 InterMune Inc. Recent Development
11.6 ProMetic Life-Sciences Inc.
11.6.1 ProMetic Life-Sciences Inc. Company Detail
11.6.2 ProMetic Life-Sciences Inc. Business Overview
11.6.3 ProMetic Life-Sciences Inc. Kidney & Renal Fibrosis Treatment Introduction
11.6.4 ProMetic Life-Sciences Inc. Revenue in Kidney & Renal Fibrosis Treatment Business (2019-2024)
11.6.5 ProMetic Life-Sciences Inc. Recent Development
11.7 La Jolla Pharmaceutical Company
11.7.1 La Jolla Pharmaceutical Company Company Detail
11.7.2 La Jolla Pharmaceutical Company Business Overview
11.7.3 La Jolla Pharmaceutical Company Kidney & Renal Fibrosis Treatment Introduction
11.7.4 La Jolla Pharmaceutical Company Revenue in Kidney & Renal Fibrosis Treatment Business (2019-2024)
11.7.5 La Jolla Pharmaceutical Company Recent Development
11.8 Genzyme Corporation
11.8.1 Genzyme Corporation Company Detail
11.8.2 Genzyme Corporation Business Overview
11.8.3 Genzyme Corporation Kidney & Renal Fibrosis Treatment Introduction
11.8.4 Genzyme Corporation Revenue in Kidney & Renal Fibrosis Treatment Business (2019-2024)
11.8.5 Genzyme Corporation Recent Development
11.9 BioLine Rx Ltd
11.9.1 BioLine Rx Ltd Company Detail
11.9.2 BioLine Rx Ltd Business Overview
11.9.3 BioLine Rx Ltd Kidney & Renal Fibrosis Treatment Introduction
11.9.4 BioLine Rx Ltd Revenue in Kidney & Renal Fibrosis Treatment Business (2019-2024)
11.9.5 BioLine Rx Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
